Effects of Metformin Monotherapy Versus Metformin Plus SGLT-2 Inhibitor Therapy on Molecular and Cellular Inflammatory Markers in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
Bennur Esen, Damla Yildiz, Ahmet Engin Atay · 2026
Read Effects of Metformin Monotherapy Versus Metformin Plus SGLT-2 Inhibitor Therapy on Molecular and Cellular Inflammatory Markers in Patients with Newly Diagnosed Type 2 Diabetes Mellitus by Bennur Esen, Damla Yildiz, Ahmet Engin Atay (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13566505.txt.
Description
Bennur Esen, Damla Yildiz and Ahmet Engin Atay compared two starter treatments for newly diagnosed type 2 diabetes in 2026. Sixty-four patients took either metformin alone or metformin plus an SGLT-2 inhibitor for six months, with inflammation markers tracked alongside blood sugar control.
Both groups improved: TNF-alpha, IL-6, HbA1c and fasting glucose all fell. After adjusting for starting values, the combination group ended with significantly lower IL-6, and uric acid was also lower in an unadjusted comparison. Other markers, including C-reactive protein and combined inflammation indices, showed no clear group difference. The study suggests the added drug mainly deepens one strand of the anti-inflammatory effect.
Catalog record
| CREATOR | Bennur Esen, Damla Yildiz, Ahmet Engin Atay |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |